(NVS) Novartis - Overview

Exchange: NYSE • Country: Switzerland • Currency: USD • Type: Common Stock • ISIN: US66987V1098

Stock:

Total Rating 61

Risk 89

Buy Signal 0.43

Drug Manufacturers - General +5.1
Pharmaceuticals +6.1

Market Cap: 316,869m
Avg Trading Vol: 380M USD

ATR: 1.65%
Peers RS (IBD): 59.41

Risk 5d forecast
Volatility	19.0%
Relative Tail Risk	-2.94%

Reward TTM
Sharpe Ratio	2.00
Alpha	51.97

Character TTM
Beta	0.326
Beta Downside	0.554

Drawdowns 3y
Max DD	19.95%
CAGR/Max DD	1.61

EPS (Earnings per Share)

EPS CAGR: 9.19%
EPS Trend: 89.2%

Last SUE: 0.27
Qual. Beats: 0

Revenue

Rev. CAGR: 1.07%
Rev. Trend: 62.6%

Last SUE: -1.59
Qual. Beats: 0

Description: NVS Novartis

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income: 13.98b TTM > 0 and > 6% of Revenue
FCF/TA: 0.14 > 0.02 and ΔFCF/TA 0.03 > 1.0
NWC/Revenue: 5.67% < 20% (prev 1.96%; Δ 3.71% < -1%)
CFO/TA 0.17 > 3% & CFO 19.13b > Net Income 13.98b
Net Debt (25.68b) to EBITDA (22.82b): 1.13 < 3
Current Ratio: 1.12 > 1.5 & < 3
Outstanding Shares: last quarter (1.93b) vs 12m ago -3.74% < -2%
Gross Margin: 75.73% > 18% (prev 0.75%; Δ 7497 % > 0.5%)
Asset Turnover: 51.56% > 50% (prev 50.59%; Δ 0.97% > 0%)
Interest Coverage Ratio: 15.23 > 6 (EBITDA TTM 22.82b / Interest Expense TTM 1.15b)

Altman Z'' 3.22

A: 0.03 (Total Current Assets 30.46b - Total Current Liabilities 27.28b) / Total Assets 115.57b
B: 0.39 (Retained Earnings 44.72b / Total Assets 115.57b)
C: 0.16 (EBIT TTM 17.49b / Avg Total Assets 108.91b)
D: 0.67 (Book Value of Equity 46.18b / Total Liabilities 69.02b)
Altman-Z'' Score: 3.22 = A

Beneish M -2.80

DSRI: 1.23 (Receivables 10.93b/8.21b, Revenue 56.15b/51.72b)
GMI: 0.99 (GM 75.73% / 75.20%)
AQI: 1.04 (AQ_t 0.63 / AQ_t-1 0.60)
SGI: 1.09 (Revenue 56.15b / 51.72b)
TATA: -0.04 (NI 13.98b - CFO 19.13b) / TA 115.57b)
Beneish M-Score: -2.80 (Cap -4..+1) = A

What is the price of NVS shares?

As of February 24, 2026, the stock is trading at USD 164.70 with a total of 1,959,513 shares traded.
Over the past week, the price has changed by -0.88%, over one month by +11.93%, over three months by +30.16% and over the past year by +56.23%.

Is NVS a buy, sell or hold?

Novartis has received a consensus analysts rating of 2.85. Therefor, it is recommend to hold NVS.

StrongBuy: 0
Buy: 2
Hold: 9
Sell: 0
StrongSell: 2

What are the forecasts/targets for the NVS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	139.8	-15.1%
Analysts Target Price	139.8	-15.1%

NVS Fundamental Data Overview February 21, 2026

P/E Trailing = 22.9259
P/E Forward = 14.1844
P/S = 5.5911
P/B = 6.7805
P/EG = 1.3644
Revenue TTM = 56.15b USD
EBIT TTM = 17.49b USD
EBITDA TTM = 22.82b USD
Long Term Debt = 27.93b USD (from longTermDebt, last quarter)
Short Term Debt = 5.78b USD (from shortTermDebt, last quarter)
Debt = 37.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 25.68b USD (from netDebt column, last quarter)
Enterprise Value = 342.55b USD (316.87b + Debt 37.11b - CCE 11.44b)
Interest Coverage Ratio = 15.23 (Ebit TTM 17.49b / Interest Expense TTM 1.15b)
EV/FCF = 21.90x (Enterprise Value 342.55b / FCF TTM 15.64b)
FCF Yield = 4.57% (FCF TTM 15.64b / Enterprise Value 342.55b)
FCF Margin = 27.85% (FCF TTM 15.64b / Revenue TTM 56.15b)
Net Margin = 24.90% (Net Income TTM 13.98b / Revenue TTM 56.15b)
Gross Margin = 75.73% ((Revenue TTM 56.15b - Cost of Revenue TTM 13.63b) / Revenue TTM)
Gross Margin QoQ = 73.44% (prev 75.35%)
Tobins Q-Ratio = 2.96 (Enterprise Value 342.55b / Total Assets 115.57b)
Interest Expense / Debt = 0.82% (Interest Expense 304.0m / Debt 37.11b)
Taxrate = 25.30% (813.9m / 3.22b)
NOPAT = 13.07b (EBIT 17.49b * (1 - 25.30%))
Current Ratio = 1.12 (Total Current Assets 30.46b / Total Current Liabilities 27.28b)
Debt / Equity = 0.80 (Debt 37.11b / totalStockholderEquity, last quarter 46.13b)
Debt / EBITDA = 1.13 (Net Debt 25.68b / EBITDA 22.82b)
Debt / FCF = 1.64 (Net Debt 25.68b / FCF TTM 15.64b)
Total Stockholder Equity = 42.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.84% (Net Income 13.98b / Total Assets 115.57b)
RoE = 32.75% (Net Income TTM 13.98b / Total Stockholder Equity 42.70b)
RoCE = 24.77% (EBIT 17.49b / Capital Employed (Equity 42.70b + L.T.Debt 27.93b))
RoIC = 17.74% (NOPAT 13.07b / Invested Capital 73.66b)
WACC = 6.44% (E(316.87b)/V(353.98b) * Re(7.12%) + D(37.11b)/V(353.98b) * Rd(0.82%) * (1-Tc(0.25)))
Discount Rate = 7.12% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.35%
[DCF Debug] Terminal Value 85.36% ; FCFF base≈14.91b ; Y1≈16.74b ; Y5≈22.37b
Fair Price DCF = 279.0 (EV 558.08b - Net Debt 25.68b = Equity 532.40b / Shares 1.91b; r=6.44% [WACC]; 5y FCF grow 14.32% → 2.90% )
EPS Correlation: 89.23 | EPS CAGR: 9.19% | SUE: 0.27 | # QB: 0
Revenue Correlation: 62.59 | Revenue CAGR: 1.07% | SUE: -1.59 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.99 | Chg30d=-0.088 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=8.97 | Chg30d=-0.253 | Revisions Net=-3 | Growth EPS=-0.1% | Growth Revenue=+1.2%
EPS next Year (2027-12-31): EPS=9.92 | Chg30d=-0.197 | Revisions Net=-1 | Growth EPS=+10.6% | Growth Revenue=+4.7%

Additional Sources for NVS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle